And, here's how to find your sweet spot for timing.

Central government employee and pensioner bodies will convene on February 25, 2026, to finalise their recommendations for the ...

Genespire is looking to take its single-dose gene therapy, GENE202, to the clinic by the end of 2026, where it will be ...

In 2025, the U.S. Food and Drug Administration (FDA or the Agency) issued a surprising number of enforcement letters to ...

For example, in the CTO setting, “IVUS can facilitate proximal cap puncture, subintimal navigation, and reentry, whereas OCT ...

ProImmune Ltd, a global leader in immunological reagents and services, announced the launch of Mastering Immunity 2026 - ...

The company is positioning this approach as a turning point for robotics, comparable to what large generative models have done for text and images.

Recovery and longevity technology company Ammortal received investment from MLBers Mike Trout, Freddie Freeman, Alex Bregman, ...

Yann LeCun is a Turing Award recipient and a top AI researcher, but he has long been a contrarian figure in the tech world. He believes that the industry’s current obsession wit ...

After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...

This week on Rule Breaker Investing, Motley Fool co-founder David Gardner is joined by Raj Sisodia and Nilima Bhat, ...

The global dry eye syndrome treatment market is projected to record high single-digit growth through 2027. Market expansion is primarily driven by the rising prevalence of dry eye disease, rapid ...